| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Priority Reports |
Department of Immunology, Institute for Cell Biology, Eberhard-Karls University Tübingen, Tübingen, Germany
Requests for reprints: Alexander Steinle, Department of Immunology, Institute for Cell Biology, University of Tübingen, Auf der Morgenstelle 15, D-72076 Tübingen, Germany. Phone: 49-7071-29-80992; Fax: 49-7071-29-5653; E-mail: alexander.steinle{at}uni-tuebingen.de.
The MHC class Irelated ligands of the immunoreceptor NKG2D are frequently expressed by tumor cells and stimulate tumor immunity mediated by CD8 T cells and natural killer (NK) cells. In humans, NKG2D ligands (NKG2DL) are encoded by the MHC-encoded MIC and nonMHC-encoded UL16-binding protein (ULBP) families of proteins. Recently, we and others showed that tumor cells release soluble MICA (sMICA), thereby counteracting NKG2D-mediated tumor immunosurveillance. Here, we now report that ULBP2 molecules are likewise released from tumor cells in a processed soluble form, and that soluble ULBP2 (sULBP2) can be detected in sera of some patients with hematopoietic malignancies. Tumor cellderived sULBP2 as opposed to cell-bound ULBP2 does not down-regulate NKG2D on NK cells. Unexpectedly, the glycosylphosphatidylinositol-anchored ULBP2 molecules are not released by phospholipases but by the action of metalloproteases. Proteolytic shedding of both NKG2D ligands MICA and ULBP2 by tumor cells was strongly enhanced after phorbol 12-myristate 13-acetate treatment and paralleled by a markedly reduced susceptibility to NKG2D-mediated cytotoxicity. Shedding of MICA and ULBP2 can be blocked by the same inhibitors, suggesting the involvement of related metalloproteases. Thus, our data suggest that reducing NKG2DL surface densities is due to a common cleavage process executed by metalloproteases that promotes escape of tumors from NKG2D-mediated immunosurveillance. (Cancer Res 2006; 66(5): 2520-6)
This article has been cited by other articles:
![]() |
A. Paschen, A. Sucker, B. Hill, I. Moll, M. Zapatka, X. D. Nguyen, G. C. Sim, I. Gutmann, J. Hassel, J. C. Becker, et al. Differential Clinical Significance of Individual NKG2D Ligands in Melanoma: Soluble ULBP2 as an Indicator of Poor Prognosis Superior to S100B Clin. Cancer Res., August 15, 2009; 15(16): 5208 - 5215. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Hedlund, A.-C. Stenqvist, O. Nagaeva, L. Kjellberg, M. Wulff, V. Baranov, and L. Mincheva-Nilsson Human Placenta Expresses and Secretes NKG2D Ligands via Exosomes that Down-Modulate the Cognate Receptor Expression: Evidence for Immunosuppressive Function J. Immunol., July 1, 2009; 183(1): 340 - 351. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Roda-Navarro and H. T. Reyburn The Traffic of the NKG2D/Dap10 Receptor Complex during Natural Killer (NK) Cell Activation J. Biol. Chem., June 12, 2009; 284(24): 16463 - 16472. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lundqvist, H. Yokoyama, A. Smith, M. Berg, and R. Childs Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells Blood, June 11, 2009; 113(24): 6120 - 6127. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Cerboni, M. Ardolino, A. Santoni, and A. Zingoni Detuning CD8+ T lymphocytes by down-regulation of the activating receptor NKG2D: role of NKG2D ligands released by activated T cells Blood, March 26, 2009; 113(13): 2955 - 2964. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Boutet, S. Aguera-Gonzalez, S. Atkinson, C. J. Pennington, D. R. Edwards, G. Murphy, H. T. Reyburn, and M. Vales-Gomez Cutting Edge: The Metalloproteinase ADAM17/TNF-{alpha}-Converting Enzyme Regulates Proteolytic Shedding of the MHC Class I-Related Chain B Protein J. Immunol., January 1, 2009; 182(1): 49 - 53. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. M. Baltz, M. Krusch, T. Baessler, B. J. Schmiedel, A. Bringmann, P. Brossart, and H. R. Salih Neutralization of tumor-derived soluble Glucocorticoid-Induced TNFR-Related Protein ligand increases NK cell anti-tumor reactivity Blood, November 1, 2008; 112(9): 3735 - 3743. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Waldhauer, D. Goehlsdorf, F. Gieseke, T. Weinschenk, M. Wittenbrink, A. Ludwig, S. Stevanovic, H.-G. Rammensee, and A. Steinle Tumor-Associated MICA Is Shed by ADAM Proteases Cancer Res., August 1, 2008; 68(15): 6368 - 6376. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Cao, X. Xi, Z. Wang, L. Dong, Z. Hao, L. Cui, C. Ma, and W. He Four novel ULBP splice variants are ligands for human NKG2D Int. Immunol., August 1, 2008; 20(8): 981 - 991. [Abstract] [Full Text] [PDF] |
||||
![]() |
B. Le Maux Chansac, D. Misse, C. Richon, I. Vergnon, M. Kubin, J.-C. Soria, A. Moretta, S. Chouaib, and F. Mami-Chouaib Potentiation of NK cell-mediated cytotoxicity in human lung adenocarcinoma: role of NKG2D-dependent pathway Int. Immunol., July 1, 2008; 20(7): 801 - 810. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. R. Siemens, N. Hu, A. K. Sheikhi, E. Chung, L. J. Frederiksen, H. Pross, and C. H. Graham Hypoxia Increases Tumor Cell Shedding of MHC Class I Chain-Related Molecule: Role of Nitric Oxide Cancer Res., June 15, 2008; 68(12): 4746 - 4753. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Clayton, J. P. Mitchell, J. Court, S. Linnane, M. D. Mason, and Z. Tabi Human Tumor-Derived Exosomes Down-Modulate NKG2D Expression J. Immunol., June 1, 2008; 180(11): 7249 - 7258. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Armeanu, M. Krusch, K. M. Baltz, T. S. Weiss, I. Smirnow, A. Steinle, U. M. Lauer, M. Bitzer, and H. R. Salih Direct and Natural Killer Cell-Mediated Antitumor Effects of Low-Dose Bortezomib in Hepatocellular Carcinoma Clin. Cancer Res., June 1, 2008; 14(11): 3520 - 3528. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. Diermayr, H. Himmelreich, B. Durovic, A. Mathys-Schneeberger, U. Siegler, U. Langenkamp, J. Hofsteenge, A. Gratwohl, A. Tichelli, M. Paluszewska, et al. NKG2D ligand expression in AML increases in response to HDAC inhibitor valproic acid and contributes to allorecognition by NK-cell lines with single KIR-HLA class I specificities Blood, February 1, 2008; 111(3): 1428 - 1436. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Maccalli, D. Nonaka, A. Piris, D. Pende, L. Rivoltini, C. Castelli, and G. Parmiani NKG2D-Mediated Antitumor Activity by Tumor-Infiltrating Lymphocytes and Antigen-Specific T-Cell Clones Isolated from Melanoma Patients Clin. Cancer Res., December 15, 2007; 13(24): 7459 - 7468. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Porcu-Buisson, M. Lambert, L. Lyonnet, A. Loundou, M. Gamerre, L. Camoin-Jau, F. Dignat-George, S. Caillat-Zucman, and P. Paul Soluble MHC Class I chain-related molecule serum levels are predictive markers of implantation failure and successful term pregnancies following IVF Hum. Reprod., August 1, 2007; 22(8): 2261 - 2266. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. Cao, X. Xi, Z. Hao, W. Li, Y. Kong, L. Cui, C. Ma, D. Ba, and W. He RAET1E2, a Soluble Isoform of the UL16-binding Protein RAET1E Produced by Tumor Cells, Inhibits NKG2D-mediated NK Cytotoxicity J. Biol. Chem., June 29, 2007; 282(26): 18922 - 18928. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Roda-Navarro and H. T. Reyburn Intercellular protein transfer at the NK cell immune synapse: mechanisms and physiological significance FASEB J, June 1, 2007; 21(8): 1636 - 1646. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. Suciu-Foca, N. Feirt, Q.-Y. Zhang, G. Vlad, Z. Liu, H. Lin, C.-C. Chang, E. K. Ho, A. I. Colovai, H. Kaufman, et al. Soluble Ig-Like Transcript 3 Inhibits Tumor Allograft Rejection in Humanized SCID Mice and T Cell Responses in Cancer Patients J. Immunol., June 1, 2007; 178(11): 7432 - 7441. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Lopez-Soto, A. Quinones-Lombrana, R. Lopez-Arbesu, C. Lopez-Larrea, and S. Gonzalez Transcriptional Regulation of ULBP1, a Human Ligand of the NKG2D Receptor J. Biol. Chem., October 13, 2006; 281(41): 30419 - 30430. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Spreu, T. Stehle, and A. Steinle Human Cytomegalovirus-Encoded UL16 Discriminates MIC Molecules by Their {alpha}2 Domains. J. Immunol., September 1, 2006; 177(5): 3143 - 3149. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Eisele, J. Wischhusen, M. Mittelbronn, R. Meyermann, I. Waldhauer, A. Steinle, M. Weller, and M. A. Friese TGF-{beta} and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells Brain, September 1, 2006; 129(9): 2416 - 2425. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |